Kyle Haraldsen is the Chief Technology Officer of Lyndra Therapeutics. Mr. Haraldsen leads product and platform R&D activities for the LYNX™ drug delivery platform and manufacturing strategy, including the build-out of the company’s automated continuous manufacturing facility. Additionally, Mr. Haraldsen co-chairs the Science & Technology Committee in partnership with Lyndra’s Chief Medical Officer Dr. Richard Scranton.
Mr. Haraldsen is a leading pharmaceutical technical officer with more than 20 years of industry experience in all facets of technical operations, product development, supply chain management, manufacturing, and project management. Prior to joining Lyndra, Mr. Haraldsen served as Chief Technical Operations Officer at Saniona, where he established the technical operations department and led efforts to develop a complex long-acting multi-product formulation of their lead asset. Before Saniona, Mr. Haraldsen held roles of increasing responsibility in technical operations and manufacturing at AMAG Pharmaceuticals, ending as Vice President – Technical Operations & Project Management, where he led the process and analytical development, manufacturing, supply chain and corporate project management functions. He helped launch nanoparticle, hormone, peptide and drug-device combination products over the course of his career.
Mr. Haraldsen holds a bachelor’s degree in chemical engineering from Northeastern University and studied drug delivery as part of a short course at MIT with Lyndra founder Dr. Robert Langer. He is an Advisory Board member for the Friends of Parkinson’s and an Industry Council member for the Dearborn STEM Academy. Mr. Haraldsen is a member of the Mount Horeb Lodge AF & AM Freemasons and enjoys traveling with his friends and family.